GLP-1 Users Cut Daily Steps 11 Percent With No Compensatory Activity Rise

The ENDO 2026 analysis linked EHR prescriptions to Fitbit data and applied within-person pre-post comparisons, isolating the medication start date as the exposure. Mean weight loss occurred yet produced no activity rebound; instead, step counts declined across age and comorbidity strata except heart failure and prior stroke. Declines were steeper in men and participants with musculoskeletal pain, suggesting pain or altered reward from rapid weight change may suppress movement. Prior STEP and SURMOUNT trials documented 25-40 percent lean-mass loss alongside fat reduction, yet omitted device-tracked behavior, leaving the behavioral mechanism unmeasured until this wearable cohort. The absence of activity increase despite lower body mass challenges the assumption that weight reduction alone restores mobility and raises the possibility that GLP-1 effects on gastric emptying or central reward circuits blunt spontaneous movement. Observational design precludes causal attribution, yet the magnitude matches the 10-15 percent step reductions seen in earlier accelerometer studies of rapid caloric restriction. Next, prospective RCTs must test whether supervised resistance plus aerobic programs begun at GLP-1 initiation can offset both muscle loss and the observed activity drop, with primary endpoints of grip strength, gait speed, and 24-month weight maintenance.